CoChat

Patient-Derived Xenografts and Matched Cell Lines Identify Pharmacogenomic Vulnerabilities in Colorectal Cancer

Open access
Lazzari, Luca, Corti, Giorgio, Picco, Gabriele, Isella, Claudio, Montone, Monica, Arcella, Pamela, Durinikova, Erika, Zanella, Eugenia R., Novara, Luca, Barbosa, Fabiane, Cassingena, Andrea, Cancelliere, Carlotta, Medico, Enzo, Sartore-Bianchi, Andrea, Siena, Salvatore, Garnett, Mathew J., Bertotti, Andrea, Trusolino, Livio, Di Nicolantonio, Federica, Linnebacher, Michael, Bardelli, Alberto, Arena, Sabrina · 2019 · Clinical Cancer Research

Published version of a preprint

Cited by 74

The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.

Abstract

Purpose: Patient-derived xenograft (PDX) models accurately recapitulate the tumor of origin in terms of histopathology, genomic landscape, and therapeutic response, but some limitations due to costs associated with their maintenance and restricted amenability for large-scale screenings still exist. To overcome these issues, we established a platform of 2D cell lines (xeno-cell lines, XL), derived from PDXs of colorectal cancer with matched patient germline gDNA available. Experimental Design: Whole-exome and transcriptome sequencing analyses were performed. Biomarkers of response and resistance to anti-HER therapy were annotated. Dependency on the WRN helicase gene was assessed in MSS, MSI-H, and MSI-like XLs using a reverse genetics functional approach. Results: XLs recapitulated the entire spectrum of colorectal cancer transcriptional subtypes. Exome and RNA-seq analyses delineated several molecular biomarkers of response and resistance to EGFR and HER2 blockade. Genotype-driven responses observed in vitro in XLs were confirmed in vivo in the matched PDXs. MSI-H models were dependent upon WRN gene expression, while loss of WRN did not affect MSS XLs growth. Interestingly, one MSS XL with transcriptional MSI-like traits was sensitive to WRN depletion. Conclusions: The XL platform represents a preclinical tool for functional gene validation and proof-of-concept studies to identify novel druggable vulnerabilities in colorectal cancer.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-18-3440

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 30 references

Research works printed but not linked: 40

  1. Kelloff, 2012, Cancer biomarkers: selecting the right drug for the right patient, Nat Rev Drug Discov, 11, 201, 10.1038/nrd3651 · DOI · Paper page
  2. The Cancer Genome Atlas Network, 2012, Comprehensive molecular characterization of human colon and rectal cancer, Nature, 487, 330, 10.1038/nature11252 · DOI · Paper page
  3. Bruna, 2016, A biobank of breast cancer explants with preserved intra-tumor heterogeneity to screen anticancer compounds, Cell, 167, 260, 10.1016/j.cell.2016.08.041 · DOI · Paper page
  4. Barretina, 2012, The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity, Nature, 483, 603, 10.1038/nature11003 · DOI · Paper page
  5. Gillet, 2013, The clinical relevance of cancer cell lines, J Natl Cancer Inst, 105, 452, 10.1093/jnci/djt007 · DOI · Paper page
  6. Byrne, 2017, Interrogating open issues in cancer precision medicine with patient-derived xenografts, Nat Rev Cancer, 17, 254, 10.1038/nrc.2016.140 · DOI · Paper page
  7. Julien, 2012, Characterization of a large panel of patient-derived tumor xenografts representing the clinical heterogeneity of human colorectal cancer, Clin Cancer Res, 18, 5314, 10.1158/1078-0432.CCR-12-0372 · DOI · Paper page
  8. Galimi, 2011, Genetic and expression analysis of MET, MACC1, and HGF in metastatic colorectal cancer: response to met inhibition in patient xenografts and pathologic correlations, Clin Cancer Res, 17, 3146, 10.1158/1078-0432.CCR-10-3377 · DOI · Paper page
  9. Ben-David, 2017, Patient-derived xenografts undergo mouse-specific tumor evolution, Nat Genet, 49, 1567, 10.1038/ng.3967 · DOI · Paper page
  10. Damhofer, 2015, Establishment of patient-derived xenograft models and cell lines for malignancies of the upper gastrointestinal tract, J Transl Med, 13, 115, 10.1186/s12967-015-0469-1 · DOI
  11. Knudsen, 2018, Pancreatic cancer cell lines as patient-derived avatars: genetic characterisation and functional utility, Gut, 67, 508, 10.1136/gutjnl-2016-313133 · DOI · Paper page
  12. Luraghi, 2018, A molecularly annotated model of patient-derived colon cancer stem-like cells to assess genetic and non-genetic mechanisms of resistance to anti-EGFR therapy, Clin Cancer Res, 24, 807, 10.1158/1078-0432.CCR-17-2151 · DOI
  13. Maletzki, 2012, Establishment, characterization and chemosensitivity of three mismatch repair deficient cell lines from sporadic and inherited colorectal carcinomas, PLoS One, 7, e52485, 10.1371/journal.pone.0052485 · DOI
  14. Niu, 2014, MSIsensor: microsatellite instability detection using paired tumor-normal sequence data, Bioinformatics, 30, 1015, 10.1093/bioinformatics/btt755 · DOI · Paper page
  15. Corti, 2019, A genomic analysis workflow for colorectal cancer precision oncology, Clin Colorectal Cancer, 18, 91, 10.1016/j.clcc.2019.02.008 · DOI · Paper page
  16. Li, 2011, RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome, BMC Bioinformatics, 12, 323, 10.1186/1471-2105-12-323 · DOI · Paper page
  17. Isella, 2017, Selective analysis of cancer-cell intrinsic transcriptional traits defines novel clinically relevant subtypes of colorectal cancer, Nat Commun, 8, 15107, 10.1038/ncomms15107 · DOI · Paper page
  18. Di Nicolantonio, 2008, Replacement of normal with mutant alleles in the genome of normal human cells unveils mutation-specific drug responses, Proc Natl Acad Sci U S A, 105, 20864, 10.1073/pnas.0808757105 · DOI · Paper page
  19. Alexandrov, 2013, Signatures of mutational processes in human cancer, Nature, 500, 415, 10.1038/nature12477 · DOI · Paper page
  20. Giannakis, 2014, RNF43 is frequently mutated in colorectal and endometrial cancers, Nat Genet, 46, 1264, 10.1038/ng.3127 · DOI · Paper page
  21. Markowitz, 1995, Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability, Science, 268, 1336, 10.1126/science.7761852 · DOI · Paper page
  22. Rodríguez-Escudero, 2011, A comprehensive functional analysis of PTEN mutations: implications in tumor- and autism-related syndromes, Hum Mol Genet, 20, 4132, 10.1093/hmg/ddr337 · DOI · Paper page
  23. Han, 2000, Functional evaluation of PTEN missense mutations using in vitro phosphoinositide phosphatase assay, Cancer Res, 60, 3147
  24. Zanella, 2015, IGF2 is an actionable target that identifies a distinct subpopulation of colorectal cancer patients with marginal response to anti-EGFR therapies, Sci Transl Med, 7, 272ra12, 10.1126/scitranslmed.3010445 · DOI · Paper page
  25. Arena, 2015, Emergence of multiple EGFR extracellular mutations during cetuximab treatment in colorectal cancer, Clin Cancer Res, 21, 2157, 10.1158/1078-0432.CCR-14-2821 · DOI · Paper page
  26. Siravegna, 2015, Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients, Nat Med, 21, 795, 10.1038/nm.3870 · DOI · Paper page
  27. Russo, 2016, Tumor heterogeneity and lesion-specific response to targeted therapy in colorectal cancer, Cancer Discov, 6, 147, 10.1158/2159-8290.CD-15-1283 · DOI · Paper page
  28. Russo, 2016, Acquired resistance to the TRK inhibitor entrectinib in colorectal cancer, Cancer Discov, 6, 36, 10.1158/2159-8290.CD-15-0940 · DOI · Paper page
  29. Leto, 2015, Sustained inhibition of HER3 and EGFR is necessary to induce regression of HER2-amplified gastrointestinal carcinomas, Clin Cancer Res, 21, 5519, 10.1158/1078-0432.CCR-14-3066 · DOI · Paper page
  30. Siravegna, 2018, Radiologic and genomic evolution of individual metastases during HER2 blockade in colorectal cancer, Cancer Cell, 34, 148, 10.1016/j.ccell.2018.06.004 · DOI · Paper page
  31. Kategaya, 2019, Werner syndrome helicase is required for the survival of cancer cells with microsatellite instability, iScience, 13, 488, 10.1016/j.isci.2019.02.006 · DOI · Paper page
  32. Lieb, 2019, Werner syndrome helicase is a selective vulnerability of microsatellite instability-high tumor cells, eLife, 8, e43333, 10.7554/eLife.43333 · DOI · Paper page
  33. Tian, 2012, A robust genomic signature for the detection of colorectal cancer patients with microsatellite instability phenotype and high mutation frequency, J Pathol, 228, 586, 10.1002/path.4092 · DOI · Paper page
  34. Jernström, 2017, Drug-screening and genomic analyses of HER2-positive breast cancer cell lines reveal predictors for treatment response, Breast Cancer, 9, 185
  35. Chen, 2012, MET activation mediates resistance to lapatinib inhibition of HER2-amplified gastric cancer cells, Mol Cancer Ther, 11, 660, 10.1158/1535-7163.MCT-11-0754 · DOI · Paper page
  36. Amirouchene-Angelozzi, Tumor evolution as a therapeutic target, Cancer Discov
  37. Dangles-Marie, 2007, Establishment of human colon cancer cell lines from fresh tumors versus xenografts: comparison of success rate and cell line features, Cancer Res, 67, 398, 10.1158/0008-5472.CAN-06-0594 · DOI · Paper page
  38. Lee, 2018, Pharmacogenomic landscape of patient-derived tumor cells informs precision oncology therapy, Nat Genet, 50, 1399, 10.1038/s41588-018-0209-6 · DOI · Paper page
  39. Pauli, 2017, Personalized in vitro and in vivo cancer models to guide precision medicine, Cancer Discov, 7, 462, 10.1158/2159-8290.CD-16-1154 · DOI · Paper page
  40. Rospo, 2019, Evolving neoantigen profiles in colorectal cancers with DNA repair defects, Genome Med, 11, 42, 10.1186/s13073-019-0654-6 · DOI

Cited by

See all 74

Metadata

Authors
Lazzari, L., Corti, G., Picco, G., Isella, C., Montone, M., Arcella, P., Durinikova, E., Zanella, E. R., Novara, L., Barbosa, F., Cassingena, A., Cancelliere, C., Medico, E., Sartore-Bianchi, A., Siena, S., Garnett, M. J., Bertotti, A., Trusolino, L., Di Nicolantonio, F., Linnebacher, M., Bardelli, A., & Arena, S.
Venue
Clinical Cancer Research
Published
2019-10-15
Volume
25
Issue
20
Pages
6243-6259
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2965934400
Cited by
74
References
30
FWCI
3.36
Type
journal article
Language
en
Open access
bronze
Funders
  • Molecular Pharmacology laboratory (CRC0080-XL)
  • European Community's Seventh Framework Programme (602901 MErCuRIC, 635342-2 MoTriColor)
  • European Research Council Consolidator (724748 - BEAT)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Patient-Derived Xenografts and Matched Cell Lines Identify Pharmacogenomic Vulnerabilities in Colorectal Cancer. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-18-3440
The paper
Lazzari, L., Corti, G., Picco, G., Isella, C., Montone, M., Arcella, P., Durinikova, E., Zanella, E. R., Novara, L., Barbosa, F., Cassingena, A., Cancelliere, C., Medico, E., Sartore-Bianchi, A., Siena, S., Garnett, M. J., Bertotti, A., Trusolino, L., Di Nicolantonio, F., . . . Arena, S. (2019). Patient-Derived Xenografts and Matched Cell Lines Identify Pharmacogenomic Vulnerabilities in Colorectal Cancer. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-18-3440

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.